학술논문
PCN114 - Cost-Effectiveness of Nivolumab in Combination with Ipilimumab in First-Line Treatment of Advanced Melanoma in Three European Countries Using 28-Month Overall Survival from Checkmate 067
Document Type
Abstract
Author
Source
In Value in Health October-November 2017 20(9):A432-A432
Subject
Language
ISSN
1098-3015